Patients covered by Medicaid or Medicare, Black patients, and those who experienced gastrointestinal side effectssuch as nausea, reported in 37% of caseswere more likely to stop their medication within the first year
We have witnessed improved joint mobility in patients using GLP-1 therapy, offering a comprehensive approach to managing joint pain alongside other metabolic benefits
Interestingly, obesity, for whose treatment GLP-1RAs are approved and validated 1,214 , is not classified under mental and behavioral disorders, and in some countries, such as the United Kingdom, it is not even formally recognized as a disease 246
The broad search algorithm combined index terms and free-text words for all GLP-1-RAs, with no restriction to study language, design (including both individual studies and their meta-analyses), setting, comparator and outcome of interest to maximize the comprehensiveness of the evidence synthesis